The dynamic change of neutrophil to lymphocyte ratio can predict clinical outcome in stage I-III colon cancer

Zhigui Li, Rui Zhao, Yaping Cui, Yong Zhou, Xiaoting Wu, Zhigui Li, Rui Zhao, Yaping Cui, Yong Zhou, Xiaoting Wu

Abstract

Whether the dynamic change of neutrophil to lymphocyte ratio (delta-NLR) can predict the outcome in various malignancies remained controversial. The delta-NLR has not been evaluated in colon cancer. Thus, we conducted the study to evaluate the predictive value of the delta-NLR in patients with colon cancer who underwent curative resection. Three-hundred and fifty-four patients with stage I-III colon cancer were retrospectively analysed. Clinicopathological features, preoperative NLR and postoperative NLR were collected. Prognostic factors were evaluated by univariate and multivariate analysis. The one, three and five-year overall survival rate in the delta-NLR < 0 group was 98.2%, 90.7% and 83.6%, respectively; and in the delta-NLR ≥ 0 group was 98.4%, 96.9% and 95.3%, respectively (log-rank test, P = 0.002). Univariate and multivariate analysis showed that there was a strong relationship between delta-NLR and overall survival. In conclusion, the delta-NLR was an independent prognostic factor for overall survival in early stage colon cancer. Patients with increased delta-NLR had an favourable clinical outcome.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Diagram showing the process of patients selection.
Figure 2
Figure 2
Receiver operating characteristic (ROC) curve analysis of the pre-NLR, post-NLR and delta-NLR.
Figure 3
Figure 3
Kaplan–Meier estimates of overall survival based on the pre-NLR.
Figure 4
Figure 4
Kaplan–Meier estimates of overall survival based on the post-NLR.
Figure 5
Figure 5
Kaplan–Meier estimates of overall survival based on the delta-NLR.

References

    1. Torre LA, et al. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65:87–108.
    1. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer epidemiology, biomarkers & prevention. 2009;18:1688–1694. doi: 10.1158/1055-9965.EPI-09-0090.
    1. Pan P, Yu J, Wang LS. Colon Cancer: What We Eat. Surgical oncology clinics of North America. 2018;27:243–267. doi: 10.1016/j.soc.2017.11.002.
    1. Crozier JE, et al. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. British journal of cancer. 2006;94:1833–1836. doi: 10.1038/sj.bjc.6603185.
    1. Scott HR, et al. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. British journal of cancer. 2002;87:264–267. doi: 10.1038/sj.bjc.6600466.
    1. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future oncology. 2010;6:149–163. doi: 10.2217/fon.09.136.
    1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–545. doi: 10.1016/S0140-6736(00)04046-0.
    1. Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Current opinion in oncology. 2013;25:50–51. doi: 10.1097/CCO.0b013e32835b651e.
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013.
    1. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer research. 2000;60:184–190.
    1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–444. doi: 10.1038/nature07205.
    1. Langsenlehner T, et al. Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients. World journal of urology. 2015;33:1661–1667. doi: 10.1007/s00345-015-1494-7.
    1. Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast cancer research: BCR. 2017;19:2. doi: 10.1186/s13058-016-0794-1.
    1. Pedrazzani C, et al. Assessment of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and platelet count as predictors of long-term outcome after R0 resection for colorectal cancer. Scientific reports. 2017;7:1494. doi: 10.1038/s41598-017-01652-0.
    1. Yang JJ, et al. Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis. World journal of gastroenterology. 2015;21:2807–2815. doi: 10.3748/wjg.v21.i9.2807.
    1. Lee S, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC cancer. 2013;13:350. doi: 10.1186/1471-2407-13-350.
    1. Peng W, et al. Neutrophil to lymphocyte ratio changes predict small hepatocellular carcinoma survival. The Journal of surgical research. 2014;192:402–408. doi: 10.1016/j.jss.2014.05.078.
    1. Chen TM, Lin CC, Huang PT, Wen CF. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. Journal of gastroenterology and hepatology. 2012;27:553–561. doi: 10.1111/j.1440-1746.2011.06910.x.
    1. Dan J, et al. Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation. Plos One. 2013;8:e58184. doi: 10.1371/journal.pone.0058184.
    1. Ohno Y, et al. Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. The Journal of urology. 2012;187:411–417. doi: 10.1016/j.juro.2011.10.026.
    1. Guo, D. et al. Preoperative to postoperative change in neutrophil-to-lymphocyte ratio predict survival in colorectal cancer patients. Future oncology (2018).
    1. Min KW, et al. Persistent elevation of postoperative neutrophil-to-lymphocyte ratio: A better predictor of survival in gastric cancer than elevated preoperative neutrophil-to-lymphocyte ratio. Scientific reports. 2017;7:13967. doi: 10.1038/s41598-017-13969-x.
    1. Rashtak S, et al. Peripheral Neutrophil to Lymphocyte Ratio Improves Prognostication in Colon Cancer. Clinical colorectal cancer. 2017;16:115–123 e113. doi: 10.1016/j.clcc.2017.01.008.
    1. Jang WS, et al. The prognostic significance of postoperative neutrophil-to-lymphocyte ratio after radical prostatectomy for localized prostate cancer. Oncotarget. 2017;8:11778–11787.
    1. Absenger G, et al. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. British journal of cancer. 2013;109:395–400. doi: 10.1038/bjc.2013.346.
    1. Miyatani K, et al. Combined analysis of the pre- and postoperative neutrophil-lymphocyte ratio predicts the outcomes of patients with gastric cancer. Surgery today. 2018;48:300–307. doi: 10.1007/s00595-017-1587-6.
    1. Fridlender ZG, et al. Polarization of Tumor-Associated Neutrophil Phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer cell. 2009;16:183–194. doi: 10.1016/j.ccr.2009.06.017.
    1. Sionov RV, Fridlender ZG, Granot Z. The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment. Cancer microenvironment. 2015;8:125–158. doi: 10.1007/s12307-014-0147-5.
    1. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000;103:481–490. doi: 10.1016/S0092-8674(00)00139-2.
    1. Acuff HB, Carter KJ, Fingleton B, Gorden DL, Matrisian LM. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer research. 2006;66:259–266. doi: 10.1158/0008-5472.CAN-05-2502.
    1. Gaida MM, et al. Polymorphonuclear neutrophils promote dyshesion of tumor cells and elastase-mediated degradation of E-cadherin in pancreatic tumors. European journal of immunology. 2012;42:3369–3380. doi: 10.1002/eji.201242628.
    1. Houghton AM, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nature medicine. 2010;16:219–223. doi: 10.1038/nm.2084.
    1. Yui S, Osawa Y, Ichisugi T, Morimoto-Kamata R. Neutrophil cathepsin G, but not elastase, induces aggregation of MCF-7 mammary carcinoma cells by a protease activity-dependent cell-oriented mechanism. Mediators of inflammation. 2014;2014:971409. doi: 10.1155/2014/971409.
    1. Morimoto-Kamata R, Mizoguchi S, Ichisugi T, Yui S. Cathepsin G induces cell aggregation of human breast cancer MCF-7 cells via a 2-step mechanism: catalytic site-independent binding to the cell surface and enzymatic activity-dependent induction of the cell aggregation. Mediators of inflammation. 2012;2012:456462. doi: 10.1155/2012/456462.
    1. Andzinski L, et al. Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. International journal of cancer. 2016;138:1982–1993. doi: 10.1002/ijc.29945.
    1. Granot Z, Jablonska J. Distinct Functions of Neutrophil in Cancer and Its Regulation. Mediators of inflammation. 2015;2015:701067. doi: 10.1155/2015/701067.
    1. Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? Carcinogenesis. 2012;33:949–955. doi: 10.1093/carcin/bgs123.
    1. Hari DM, et al. AJCC Cancer Staging Manual7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? Journal of the American College of Surgeons. 2013;217:181–190. doi: 10.1016/j.jamcollsurg.2013.04.018.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir